Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification.

Mol Ther · 2024 · PMC11405179 · PMID 38894542

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

barely significantno p-value reported

Only minor, barely significant enhancements were observed on LS180 at early time points (0 or 6 h) and only at a 1:5 effector:target ratio, confirming that very early after detachment from HER2amp cancer cells most of the CEA-CAR activity is lost within few hours.

also in 169 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.